Lassa Virus Treatment Options
Open Access
- 7 April 2021
- journal article
- review article
- Published by MDPI AG in Microorganisms
- Vol. 9 (4) , 772
Abstract
Lassa fever causes an approximate 5000 to 10,000 deaths annually in West Africa and cases have been imported into Europe and the Americas, challenging public health. Although Lassa virus was first described over 5 decades ago in 1969, no treatments or vaccines have been approved to treat or prevent infection. In this review, we discuss current therapeutics in the development pipeline for the treatment of Lassa fever, focusing on those that have been evaluated in humans or animal models. Several treatments, including the antiviral favipiravir and a human monoclonal antibody cocktail, have shown efficacy in preclinical rodent and non-human primate animal models and have potential for use in clinical settings. Movement of the promising preclinical treatment options for Lassa fever into clinical trials is critical to continue addressing this neglected tropical disease.Keywords
This publication has 95 references indexed in Scilit:
- T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 VirusesIn VitroJournal of Virology, 2013
- Ribavirin Can Be Mutagenic for ArenavirusesJournal of Virology, 2011
- Pathogenesis of lassa fever in cynomolgus macaquesVirology Journal, 2011
- Evaluation of Lassa antiviral compound ST-193 in a guinea pig modelAntiviral Research, 2011
- Assessing changes in vascular permeability in a hamster model of viral hemorrhagic feverVirology Journal, 2010
- Early and Strong Immune Responses Are Associated with Control of Viral Replication and Recovery in Lassa Virus-Infected Cynomolgus MonkeysJournal of Virology, 2009
- Characterization of Lassa Virus Cell Entry and Neutralization with Lassa Virus PseudoparticlesJournal of Virology, 2009
- Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodentsAntiviral Research, 2008
- Identification of a Broad-Spectrum Arenavirus Entry InhibitorJournal of Virology, 2008
- In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus InfectionsAntimicrobial Agents and Chemotherapy, 2007